Search

Search Constraints

You searched for: Author/Creator Anthopoulos, Prodromos

Search Results

1. Clinical outcomes after TAVR with heparin or bivalirudin as periprocedural anticoagulation in patients with and without peripheral arterial disease: Results from the BRAVO‐3 randomized trial. Issue 3 (5th December 2019)

2. Effect of valve design and anticoagulation strategy on 30‐day clinical outcomes in transcatheter aortic valve replacement: Results from the BRAVO 3 randomized trial. Issue 6 (19th July 2017)

3. Impact of acute infarct-related artery patency before percutaneous coronary intervention on 30-day outcomes in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention in the EUROMAX trial. Issue 6 (1st September 2018)

4. Impact of acute infarct-related artery patency before percutaneous coronary intervention on 30-day outcomes in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention in the EUROMAX trial. Issue 6 (September 2018)

5. Impact of anemia on short‐term outcomes after TAVR: A subgroup analysis from the BRAVO‐3 randomized trial. Issue 6 (12th May 2021)

6. Impact of Arterial Access Site on Outcomes After Primary Percutaneous Coronary Intervention: Prespecified Subgroup Analysis From the EUROMAX Trial. (June 2015)

7. Impact of diabetes mellitus on short term vascular complications after TAVR: Results from the BRAVO-3 randomized trial. (15th December 2019)

8. Impact of percutaneous closure device type on vascular and bleeding complications after TAVR: A post hoc analysis from the BRAVO‐3 randomized trial. Issue 7 (22nd May 2019)

9. Impact of pre‐existing or new‐onset atrial fibrillation on 30‐day clinical outcomes following transcatheter aortic valve replacement: Results from the BRAVO 3 randomized trial. Issue 6 (20th June 2017)

10. Review article: randomised controlled trials in inflammatory bowel disease—common challenges and potential solutions. Issue 6 (7th February 2022)